Think global, act local: rethinking commercialisation models

R&D
Card image cap

The global market for life sciences is changing rapidly. Fuelled by technological advancements and a global pandemic, there are more opportunities than ever for companies to get innovative and life-saving therapies to the patients that need them.

But when it comes to marketing new therapies, the seemingly complex nature of global markets can be intimidating, with regulatory, cultural and language insight required to commercialise a brand image across different markets. Traditional launch models have reinforced this perception of complexity, most notably across the European Union, as companies have to seek out multiple siloed and fragmented partnerships to access the correct information and infrastructure before they have even entered a market.

In reality, global markets have a lot in common. But to identify and tap into budding opportunities, life science companies must rebuild their understanding of commercialisation to reflect the changing market landscape.

As EVERSANA™ executive vice president, EMEA Mike Ryan explains, “There is a lot of opportunity for companies to effectively replicate a commercial infrastructure that’s reusable time and time again to effectively create all of the infrastructure necessary to commercialise across a maximum number of markets.”

• Read the full article in pharmaphorum's Deep Dive digital magazine

17 March, 2022

Deep Dive

Deep Dive

Digital
Card image cap

Company profile: Vinehealth

The Vinehealth digital personalised cancer support platform maximises quality of life and clinical outcomes for cancer patients by delivering personalised cancer support at scale.<

Digital
Card image cap

Timeline: a history of medical imaging

Today, medical imaging technologies such as X-ray and MRI machines are so ubiquitous across healthcare settings that it is difficult to imagine a life without them.